SCHEMBL6785503

SCHEMBL6785503

O=C(NC1CCNCC1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 3/20 0.62
HDAC6 Q9UBN7 2/20 0.62
SMYD3 Q9H7B4 3/20 0.51
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
HTR2C P28335 2/20 0.50
SLC6A5 Q9Y345 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
PAK1 Q13153 1/20 0.49
TRPV1 Q8NER1 1/20 0.49
DRD4 P21917 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7647671 0.89 RAB9A (0.59) HDAC4SLC6A5NPC1RAB9ADRD4
SCHEMBL7652620 0.85 NPC1 (0.68) HDAC4HDAC6NPC1RAB9ATRPV1
SCHEMBL7647577 0.85 NPC1 (0.63) HDAC4HDAC6SLC6A5NPC1RAB9A
SCHEMBL12061861 0.84 MEN1 (0.58) HDAC4HDAC6SMYD3HDAC3HDAC1
SCHEMBL1424863 0.84 NPC1 (0.71) HDAC4HDAC6SMYD3HDAC3HDAC1
Hydrochloric Acid SCHEMBL4602954 0.83 NPC1 (0.69) HDAC4HDAC6SMYD3HDAC3HDAC1
SCHEMBL17927246 0.82 HDAC4 (0.65) HDAC4NPC1RAB9A
SCHEMBL13575468 0.81 KHK (0.54) HDAC4HDAC6SMYD3HDAC3HDAC1
SCHEMBL3036579 0.81 HDAC4 (0.56) HDAC4HDAC6SMYD3HDAC3HDAC1
SCHEMBL279571 0.81 RAB9A (0.71) HDAC4HDAC6SMYD3HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040034028-A1 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors MERCK PATENT GMBH (DE) 2004-02-19 US disclosed
CN-1132828-C O-substd. hydroxy coumaranone derivs as antineoplastic and antitransfer agent ROCH DIAGNOSIS EQUIPMENT AG (DE) 2003-12-31 CN disclosed
US-6307051-B1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTAGONISTS AND HAVE ANTITUMOR AND ANTIMETASTATIC ACTIVITY. ROCHE DIAGNOSTICS GMBH (DE) 2001-10-23 US disclosed
CN-1266850-A O-substd. hydroxy coumaranone derivs as antineoplastic and antitransfer agent ROCH DIAGNOSIS EQUIPMENT AG (DE) 2000-09-20 CN disclosed
EP-1026165-A1 O-substituted Hydroxycoumaranone derivatives as antitumor and antimetastatic agents Roche Diagnostics GmbH (DE) 2000-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034028-A1 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors LIPC, CETP, MTTP HDAC4 3777/4885HDAC6 3836/4885SMYD3 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.